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P.A. Gaines*Sheffield Vascular Institute, Northern General Hospital, Sheffield S5 7AU, UKIn this journal a study to evaluate the clinical outcomes
of an iliac stent is published. The stent already had a
CE (Conformite´ Europe´en) mark and was therefore
freely available within Europe for clinical use. For an
iliac stent to have a CE mark and therefore be freely
available on the market the European Medical Devices
Directive describes the essential requirements that
must be met. In brief these are:1. A device that does not compromise the clinical
condition or safety of the patient, the safety and
health of users or, where possible, any third party.2. The device must achieve its intended purpose as
designated by the manufacturer and3. Any risks associated with the use of the device are
judged by informed clinical opinion to be accep-
table when weighed against the benefits to the
patients and compatible with a high level of
protection of health and safety.
It also introduces controls covering the safety,
performance, specification, design, manufacture, lab-
elling and packaging of devices. In order to comply
with the directive the manufacturer may either (a)
compile the relevant scientific literature currently
available on the intended purpose of the device and
the techniques employed, together with, if appropri-
ate, a written report containing an evaluation of the
compilation, or (b) provide the results and conclusions
of a specifically designed clinical investigation. The
clinical investigation is only required if the device
introduces completely new concepts, or represents a
modification of a device that contains a novel feature
or modifies an important physiological effect, or where
the device incorporates materials previously untested
in humans, or where a device which may already be
CE marked, is proposed for a new purpose or function.effield Vascular Institute, Northern General Hospital,
, Sheffield S5 7AU, UK.
: p.a.gaines@sheffield.ac.uk.
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to achieve the essential requirements.
Many manufacturers choose a compilation of the
scientific literature to obtain a CE mark for iliac stents.
This is despite the literature accompanying the market
release of a new stent invariably detailing new an
unique advantageous features of the device. This
leaves the clinician in a quandary for whilst an iliac
stent may have a CE mark based on a compilation of
relevant literature, such a route often does not show
equivalence in all areas of interest (i.e. technology,
critical performance, design, principles of operation,
population involved, conditions of use and clinical
purpose). Since there are no standard criteria by which
the various notified bodies throughout Europe judge
the performance of the new devices, there can be no
surprise that manufacturers choose their body to suite
their own needs.
Many new devices are released without any data on
long-term efficacy or safety being available. And once
the CE marking process, as described by the European
Medical Devices Directive, has been completed there is
currently no enforceable standardised mechanism for
obtaining relevant clinical outcomes on these new
devices. Most stents are produced using either nitinol
or stainless steel. Each new stent has a unique feature,
usually in the form of the design of the stent rather
than then metal used, which may potentially result in
adverse clinical outcomes. The Directives do not
mandate a pre-market clinical investigation and
reliance is placed upon the manufacturers to conduct
a post-marketing trial. This does not always happen
which means that a substantial number of patients
could be treated with new stents without any specific
supporting clinical literature.
Whilst I applaud the progress that has been made in
the evaluation of medical devices following the
introduction of the European Medical Devices Direc-
tive there appear to be shortcomings in the process
that need to be addressed.Eur J Vasc Endovasc Surg 29, 105 (2005)
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